Imatinib and everolimus in patients with progressing advanced chordoma: A phase 2 clinical study.
Silvia StacchiottiCarlo MorosiSalvatore Lo VulloAlessandra CasaleElena PalassiniAnna Maria FrezzaGabriella DinoiAntonella MessinaAlessandro GronchiAdalberto CavalleriElisabetta VenturelliDaniele MorelliSilvana PilottiPaola ColliniSilvia BrichElena TamboriniLuigi MarianiPaolo G CasaliPublished in: Cancer (2018)
Imatinib plus everolimus showed a limited activity in progressing advanced chordoma. Interestingly, the amount of tumor cells activated for mammalian target of rapamycin effectors correlated with the response. Toxicity was not negligible.